Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for C4 Therapeutics, Inc. Common Stock (CCCC).
- Disclosed ownership: 9.3%.
- Date of event: 31 Dec 2025.
MORGAN STANLEY - 31 Dec 2025 SCHEDULE 13G/A Report for C4 Therapeutics, Inc. Common Stock (CCCC)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- C4 Therapeutics, Inc. Common Stock
- Symbol
- CCCC
- Shares outstanding
- 96,496,677 shares
- Disclosed Ownership
- 8,974,191 shares
- Ownership
- 9.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 11 Feb 2026, 12:58:54 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 07 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 9.3% ownership in C4 Therapeutics, Inc. Common Stock (CCCC) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 07 Aug 2025.
- Current filing was accepted on 11 Feb 2026, 12:58.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 9.3% | 8,974,191 | 0 | 8,973,891 | Chris O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley & Co. LLC | 9.2% | 8,897,942 | 0 | 8,897,942 | Chris O'Hara | Authorized Signatory, Morgan Stanley & Co. LLC |